The Dutch Ministry of Foreign Affairs made a EUR 18.4-million, four-year investment in Aeras Global TB Vaccine Foundation, a product development partnership that is collaborating with Crucell, KNCV Tuberculosis Foundation, Netherlands Cancer Institute, and other Dutch organizations to develop new TB vaccines.
In Aeras’ prime-boost strategy, an improved TB vaccine, the prime, will be given initially, and another type of vaccine, the boost, will be given at a specified period of time after the prime vaccination. One of the foundation’s products, Aeras 402/Crucell Adenovirus35 TB vaccine, recently entered clinical trials.